Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gloria Carmona is active.

Publication


Featured researches published by Gloria Carmona.


Vaccine | 2003

Effectiveness of a mass hepatitis A vaccination program in preadolescents.

A. Domínguez; Salleras L; Gloria Carmona; J. Batalla

A program of mass hepatitis A+B vaccination in preadolescents in schools was begun in the Catalonia in the last quarter of 1998. This study investigated the impact of the program by comparing the incidence of hepatitis A in vaccinated and unvaccinated cohort. The greatest reduction of the incidence rate of hepatitis A was observed in the 10-14 years age group, from 10.3 per 100000 persons-year in the period 1996-1998 to 1.8 per 100000 persons-year in the period 1999-2001. The global incidence decreased from 6.2 to 2.6 per 100000 persons-year. After analysis of cases occurring in the vaccinated and non vaccinated cohort, the effectiveness of the vaccination program was estimated at 97.0% (95% CI: 78.6-99.6).


Vaccine | 2002

The epidemiology of invasive Streptococcus pneumoniae disease in Catalonia (Spain): A hospital-based study

Angela Domínguez; L. Salleras; Neus Cardeñosa; Pilar Ciruela; Gloria Carmona; Ana Martínez; Nuria Torner; M Fuentes

The aim of this study was to investigate the incidence of invasive pneumococcal disease (IPD) in Catalonia. A hospital-based incidence study of the period 1997-1999 was carried out by reviewing the isolations of Streptococcus pneumoniae obtained from normally sterile sites reported by the hospitals that voluntarily participate in the Microbiological Reporting System of Catalonia (MRSC), and those obtained by active retrospective surveillance of cases recorded by microbiology laboratories of the remaining hospitals. Cases of pneumonia were included only if the blood culture was positive. The age, sex and clinical presentation of each patient were recorded. The global incidence of hospital-based IPD was 10.5 per 100,000 persons-year, and was much higher in subjects <2 years of age (59.6) and in those aged > or = 65 years (27.9). In subjects > or = 65 years, bacteremic pneumococcal pneumonias were more frequent in the months from December to March than they were in children <2 years of age (P<0.0001). The global incidence of IPD (10.5 per 100,000 persons-year) is high in Catalonia, greater than that of meningococcal or Haemophilus influenzae invasive disease. In children <2 years, the incidence is nearly six times higher (59.6 per 100,000 persons-year) with pneumonias (rate of 26.2 per 100,000 persons-year) and non-focal bacteremias (rate of 22.1 per 100,000 persons-year) being especially frequent.


Vaccine | 2008

Impact and effectiveness of a mass hepatitis A vaccination programme of preadolescents seven years after introduction

Angela Domínguez; Manuel Oviedo; Gloria Carmona; Joan Batalla; Miquel Bruguera; L. Salleras; Antoni Plasència

AIM To investigate the impact of a mass hepatitis A vaccination programme in preadolescents seven years after introduction in terms of its effectiveness and the prevented fraction. SETTING The age distribution of notified cases and incidence rates in Catalonia (Spain) in the periods before (1992-1998) and after (1999-2005) introduction of the vaccination programme were compared. MAIN RESULTS The incidence rates in the whole population were 5.51 per 100,000 person-years in the 1992-1998 period and 2.98 in the 1999-2005 period. The rate reduction in the 10-19 years age group was 72.43% and was more than 45% in the 5-9 years and 20-29 years age groups. The effectiveness of the vaccination programme was 99.04 (95% CI: 93.11-99.88) and the prevented fraction in the 12-19 years age group was 90.13% (95% CI: 84.47-90.89). CONCLUSIONS The universal vaccination programme of preadolescents has had an important impact on hepatitis A in Catalonia, not only in vaccinated cohorts but also in non-vaccinated age groups due to a herd immunity effect.


Vaccine | 2011

Epidemiology of pertussis in a country with high vaccination coverage

Inma Crespo; Neus Cardeñosa; Pere Godoy; Gloria Carmona; M. Rosa Sala; Irene Barrabeig; Josep Álvarez; Sofia Minguel; Neus Camps; Joan A. Caylà; Joan Batalla; Gemma Codina; Angela Domínguez

INTRODUCTION Pertussis has been a preventable disease in Catalonia since 1965, but the annual number of cases remains high. The aim of this study was to analyze the epidemiology of pertussis in Catalonia and its implications for control purposes. METHODS An epidemiological study was carried out in Catalonia between 2004 and 2008. Pertussis cases reported to the Department of Health were collected and disease reports were filled out with the case information. Incidence rates, rate ratios (RR) and their 95% confidence intervals (CI) were calculated. RESULTS 963 cases were reported: 555 (57.6%) were confirmed and 408 (42.4%) were suspected cases. The reported incidence rate was 2.01 × 10(-5) person years in 2004 and 4.34 in 2008. The biggest increase in cases between 2004 and 2008 was observed in the ≥35 years age group (RR: 6.98; 95%CI: 2.11-36.36). 303 (31.5%) patients were hospitalized, of whom 93.7% were aged <1 year. Clinical differences were observed in paroxysmal cough (83.8% in suspected and 76.4% in confirmed cases, p=0.005), posttussive vomiting (47.1% and 36.1%, respectively, p=0.001), apnoea (13.7% and 21.3%, respectively, p=0.003) and fever (20.1% and 12.4%, respectively, p=0.001). CONCLUSION Pertussis incidence rates increased during the study period, with the greatest increase occurring in the ≥35 years age group. A booster dose of vaccine in young people could reduce the circulation of B. pertussis in adolescents and adults and indirectly reduce the incidence in children.


Vaccine | 1999

Measles immunity and vaccination policy in Catalonia

A. Domínguez; Josep Vidal; Pere Plans; Gloria Carmona; Pere Godoy; J. Batalla; L. Salleras

The prevalence of antibodies against measles in a representative sample of the school population in Catalonia was established and the results compared with previous studies. The study was carried out in 1996 using blood samples obtained from schoolchildren aged 6-7 years, 10-11 years, 13 14 years and 15-16 years. 1231 schoolchildren were studied. The global prevalence of antibodies was 96.3%, and a considerable increase was observed with respect to the prevalence in 1986 (89.4%). The level of antibodies was 94% at 6-7 years and 10-11 years, 99.7% at 13-14 years and 98.3% at 15 16 years. These data would suggest the advancement of the administration of the second dose of measles-mumps rubella vaccine to 4 6 years instead of at 11 years.


Journal of Viral Hepatitis | 2008

Epidemiology of hepatitis A before and after the introduction of a universal vaccination programme in Catalonia, Spain.

Angela Domínguez; Manuel Oviedo; Gloria Carmona; J. M. Jansá; Eva Borràs; L. Salleras; Antoni Plasència

Summary.  A universal vaccination program for preadolescents, aged 12 years, with the hepatitis A + B vaccine was introduced in 1998 in Catalonia (Spain) with the aim of protecting the whole population against hepatitis A. The hepatitis A + B vaccine program replaced the hepatitis B vaccination program for preadolescent started in 1991. The impact of the hepatitis A + B vaccination program was studied by assessment of the trend of reported cases of hepatitis A. All cases of viral hepatitis reported from 1992 to 2006 were included in the study. To evaluate changes in the epidemiology of hepatitis A, two periods were considered: a prevaccination period (1992–1998) and a post‐vaccination period (2001–2006). The ratios of the rates were calculated according to age and sex. The comparison of rates and proportions was made by calculation of the normal z statistic. A total of 7536 cases of viral hepatitis were reported, of which 4109 (54.52%) were hepatitis A. The incidence rate of hepatitis A fell from 5.44 per 100 000 person‐years in the prevaccination period to 3.02 in the post‐vaccination period. In males, the rate fell from 6.85 to 3.89 and in females from 4.10 to 2.18. The male‐female ratio of incidence rates was lower in the post‐vaccination period. In males the global decline of incidence rate was 43.26% and in females 46.96%. The greatest decline occurred in the 15 to 19 years age group in both sexes (79.1% in men and 78.34% in women) but declines in the 10–14 years age group were also very important (69.21% and 67.88%, respectively). In conclusion, hepatitis A incidence fell in Catalonia in the post‐vaccination period in vaccinated adolescents and also in other unvaccinated groups who have benefited from the indirect effects of the vaccination program.


International Journal of Tuberculosis and Lung Disease | 2013

Smoking in tuberculosis patients increases the risk of infection in their contacts

Pere Godoy; J. A. Caylà; Gloria Carmona; Neus Camps; Josep Álvarez; Miquel Alsedà; Sofia Minguell; Anna Rodés; Neus Altet; J.M. Pina; Irene Barrabeig; Angels Orcau; Ignasi Parrón; J. March; Núria Follia; M. Sabater; Angela Domínguez

OBJECTIVE To determine the risk of latent tuberculous infection (LTBI) among contacts of smokers with tuberculosis (TB). METHODS A study was conducted to determine the prevalence of LTBI among contacts of TB cases aged >14 years in Catalonia, Spain. A survey was carried out for each TB case and their contacts. LTBI was diagnosed using the tuberculin skin test (≥5 mm). The risk of LTBI associated with smoking was determined by multi-variate logistic regression analysis, with adjusted odds ratio (aOR) and their 95% confidence intervals (CI). RESULTS The smoking prevalence among TB cases was 40.7% (439/1079). The prevalence of LTBI among their contacts was 29.7% (2281/7673). It was higher among contacts of smoking index cases (35.3%) than among those of non-smokers (25.7%). Smoking was independently associated with an increased risk of LTBI among contacts (aOR 1.5, 95%CI 1.3-1.7), and was estimated to be responsible for 12.8% of infections. CONCLUSIONS Index case smoking increases the risk of LTBI and should be systematically investigated. A reduction in smoking could lower the risk of infection substantially.


Vaccine | 2009

Is the vaccination coverage established enough to control pertussis, or it is a re-emerging disease?

Neus Cardeñosa; Marcos Romero; Mariela Quesada; Manuel Oviedo; Gloria Carmona; Gemma Codina; Josep M. Jansà; Angela Domínguez

Although vaccination coverage is high in Catalonia, Spain, pertussis is still a significant cause of morbidity and mortality among infants, overall due to adolescent and adult contacts. An epidemiological study from voluntary health care centres to detect confirmed pertussis cases was carried out in Catalonia. From 465 pertussis-suspect-cases, we identified 126 confirmed events, 73 of them confirmed by laboratory tests. Most of cases were infants less than 4 months old 23 (18.3%), adolescents 22 (17.4%) and adults 46 (36.5%). Sixty-one cases (49.6%) presented paroxysmal cough, 33 (26.8%) post-tussive vomiting and inspiratory whoop, and 27 (22%) apnoea. The vaccination status was not known for 46 (36.5%) patients. Of the total vaccine status documented, 59 (73.8%) patients had received at least one dose. Sixty patients (47.6%) were considered index cases, 32 of them (53.3%) were children under 1-year old. Among contacts identified as pertussis cases, 63.6% (42/66) were older than 14 years of age. These contacts were parents (30), siblings (19), grandmother (4), and others (13). These results confirm protective efficacy of pertussis vaccine only during few time. Regular pertussis boosters in teenagers, and/or in adults who take care of young children, could decrease the incidence of the infection.


Vaccine | 2011

Influenza vaccine coverage, influenza-associated morbidity and all-cause mortality in Catalonia (Spain)

M. Pilar Muñoz; Núria Soldevila; Anna Martínez; Gloria Carmona; Joan Batalla; Lesly M. Acosta; Angela Domínguez

The objective of this work was to study the behaviour of influenza with respect to morbidity and all-cause mortality in Catalonia, and their association with influenza vaccination coverage. The study was carried out over 13 influenza seasons, from epidemiological week 40 of 1994 to week 20 of 2007, and included confirmed cases of influenza and all-cause mortality. Two generalized linear models were fitted: influenza-associated morbidity was modelled by Poisson regression and all-cause mortality by negative binomial regression. The seasonal component was modelled with the periodic function formed by the sum of the sinus and cosines. Expected influenza mortality during periods of influenza virus circulation was estimated by Poisson regression and its confidence intervals using the Bootstrap approach. Vaccination coverage was associated with a reduction in influenza-associated morbidity (p<0.001), but not with a reduction in all-cause mortality (p=0.149). In the case of influenza-associated morbidity, an increase of 5% in vaccination coverage represented a reduction of 3% in the incidence rate of influenza. There was a positive association between influenza-associated morbidity and all-cause mortality. Excess mortality attributable to influenza epidemics was estimated as 34.4 (95% CI: 28.4-40.8) weekly deaths. In conclusion, all-cause mortality is a good indicator of influenza surveillance and vaccination coverage is associated with a reduction in influenza-associated morbidity but not with all-cause mortality.


Scandinavian Journal of Infectious Diseases | 2004

The case-fatality rate of meningococcal disease in Catalonia, 1990-1997.

A. Domínguez; Neus Cardeñosa; Helena Pañella; Angels Orcau; Maria Companys; Miquel Alsedà; Manuel Oviedo; Gloria Carmona; Sofia Minguell; Salleras L

The objective was to analyse the case-fatality rate (CFR) of meningococcal disease (MD) in Catalonia, Spain. A retrospective study was carried out. Clinical histories of cases of MD reported for the period 1990–1997 in Catalonia were reviewed. For all cases, the variables gender, age, clinical type, y of presentation, province, phenotype and death by meningococcal disease were collected. The association between death and the other variables was studied by bivariate and unconditional logistic regression analysis. In the 2343 cases studied there were 146 deaths (6.2%) due to meningococcal disease. The CFR was higher in females (OR: 1.5, 95%CI: 1.1–2.1), in the 20 to 49 y (OR: 2.4, 95%CI: 1.2–4.9) and≥50 y (OR: 5.3, 95%CI: 2.8–10.1) age groups, in cases with septicaemia (OR: 2.4, 95%CI: 1.6–3.5), in the cases produced by serogroup A (OR: 4.7, 95%CI: 1.0–23.4) and in cases occurring during 1993 (OR: 2.1, 95%CI: 1.1–4.1) or in the province of Lleida (OR: 2.9, 95%CI: 1.2–7.2). In the multivariate analysis, death was associated with the 20–49 y age group (OR: 3.9, 95% CI: 1.8–8.4), the≥50 y age group (OR: 7.3, 95%CI: 3.6–14.7), septicaemia (OR: 3.1; 95%CI: 2.0–4.7) and residing in the province of Lleida (OR: 3.2; 95%CI: 1.2–8.5). The CFR of meningococcal disease in Catalonia was not associated with the emergent phenotype C:2b:P1.2,5 strain, which caused an outbreak in other regions of Spain.

Collaboration


Dive into the Gloria Carmona's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sofia Minguell

Generalitat of Catalonia

View shared research outputs
Top Co-Authors

Avatar

A. Domínguez

Generalitat of Catalonia

View shared research outputs
Top Co-Authors

Avatar

Josep Álvarez

Generalitat of Catalonia

View shared research outputs
Top Co-Authors

Avatar

Neus Camps

Generalitat of Catalonia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nuria Torner

Generalitat of Catalonia

View shared research outputs
Researchain Logo
Decentralizing Knowledge